Interrelation of interleukin profile and the blood oxidant system in elderly patients with late-stage age-related macular degeneration
Background: In the elderly, age-related macular degeneration has a high prevalence and often causes a decrease and complete loss of vision. However, immunological mechanisms of development of this pathology and their relationship with changes in the oxidant system in elderly patients remain insufficiently studied. The aim of the study: To analyze the relationship between interleukin profile and the serum oxidant system in elderly patients with late-stage age-related macular degeneration (AREDS-4). Materials and methods: Serum interleukin levels and the oxidant system parameters were studied in 57 patients aged 60-74 years with stage 4 age-related macular degeneration. The control group included 52 people of the same age without the above pathology. The content of interleukins was determined on the flow cytometer BD FACS Canto 2, and lipid peroxidation-on the spectrophotometer SF-16. Results: There was a significant increase in the analyzed serum interleukins and, to a greater extent, IL-1β, IL-8 in the group of patients with age-related macular degeneration in comparison with the age control. The content of anti-inflammatory interleukins and interferons-α, ɣ significantly decreased in patients with this disease, the level of lipid peroxidation products significantly increased. Inverse correlations were found between anti-inflammatory interleukins and indicators of the oxidant system. There are inverse correlations with changes in anti-inflammatory interleukins and indicators of free radical oxidation. Conclusion: As a result of the study, the features of the interleukin profile and the oxidative system of blood serum in elderly patients with advanced macular degeneration with advanced stage have been established that will enable to rationalize the diagnosis and pathogenetic therapy for age-related macular degeneration in the elderly.
Konyaev DA. Interrelation of interleukin profile and the blood oxidant system in elderly patients with late-stage age-related macular degeneration. Research Results in Biomedicine. 2020;6(1):118-125.
(In Russian) DOI: 10.18413/2658-6533-2020-6-1-0-10
While nobody left any comments to this publication.
You can be first.
1. Abdullayeva EA. [The Role of complement system and other inflammatory factors in the development of age-related macular degeneration]. Kazanskij medicinskij zhurnal. 2018;99(4):657-664. Russian. DOI: https://doi.org/10.17816/KMJ2018-657
2. Telegina DV, Kozhevnikova OS, Kolosova NG. [Molecular mechanisms of cell death in the retina in the development of age-related molecular degeneration]. Uspekhi gerontologii. 2016;29(3):424-432. Russian
3. Tur EV, Kuznetsov AA, Bystrov AM. [Evaluation of tear cytokine level in patients with neovascular age-related macular degeneration]. Rossijskij immunologicheskij zhurnal. 2016;10(19)(3):361-362. Russian
4. Saldanha IJ, Lindsley K, Do DV, et al. Comparison of Clinical Trial and Systematic Review Outcomes for the 4 Most Prevalent Eye Diseases. JAMA Ophthalmol. 2017;135(9):933-940. DOI: 10.1001/jamaophthalmol.2017.2583
5. Wang Y, Lv H, Liu Y, et al. Characteristics of symptoms experienced by persons with dry eye disease while driving in China. Eye (Lond). 2017 June 16;31(11):1550-1555. DOI: https://doi.org/10.1038/eye.2017.88
6. WHO. Prevention of Blindness and Visual Impairment. Priority Eye Diseases [Internet]. 2017 [cited 2018 May 03]. Available from: https://www.who.int/blindness/causes/priority/en/index7.html.
7. Khan M, Agarwal K, Loutfi M, et al. Present and possible therapies for age-related macular degeneration. ISRN ophthalmol. 2014 Apr;2014:608390. DOI: http://dx.doi.org/10.1155/2014/608390
8. Akpek EK, Smith RA. Overview of age-related ocular conditions. Amer. J. Managed Care. 2013 May;19(5):s67-s75.
9. Hamano T, Li X, Tanito M, et al. Neighborhood Deprivationand Riskof Age-Related Eye Diseases: A Follow-up Studyin Sweden. Ophthalmic Epidemiol. 2015 Sep 23;22(5):308-320. DOI: https://doi.org/10.3109/09286586.2015.1056537
10. Nowak MS, Smigielski J. The Prevalence of Age-Related Eye Diseases and Cataract Surgery among Older Adults in the City of Lodz. Poland J Ophthalmol. 2015 Feb 19;2015:605814. DOI: https://doi.org/10.1155/2015/605814
11. Erke MG, Bertelsen G, Peto T, et al. Prevalence of age-related macular degeneration in elderly Caucasians: the Tromso eye study. Ophthalmology. 2012 Sep;119(9):1737-1743. DOI: https://doi.org/10.1016/j.ophtha.2012.03.016
12. Thapa SS, Thapa R, Paudyal I, et al. Prevalence and pattern of vitreo-retinal diseases in Nepal: the Bhaktapur glaucoma study. BMC Ophthalmology. 2013 March 28;13:9. DOI: https://doi.org/10.1186/1471-2415-13-9
13. Konyaev DA. [Medical and epidemiological analysis of morbidity and anti-VEGF treatment of exudative forms of age-related macular degeneration in the Tambov region for 6 years]. Vestn. Tambovskogo Universiteta. 2016;21:1583-1586. Russian.
14. Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular degeneration. Nature Reviews Immunology. 2013 May 24;13:438-451. DOI: https://doi.org/10.1038/nri3459
15. Penfold PL. Inflammation and age-related macular degeneration. JAMA. 2004;291(6):704-710.
16. Zarbin MA. Current concepts in the pathogenesis of age – related macular degenerationes. Archives of Ophthalmology. 2004;122(4):598-614. DOI: 10.1001/archopht.122.4.598
17. Penfold PL, Madigan MC, Gillies MC, et al. Immunological and aetiological aspects of macular degeneration. Prog. Retin. Eye. Res. 2001 May;20(3):385-414. DOI: https://doi.org/10.1016/S1350-9462(00)00025-2
18. Penfold PL. Inflammation and age-related macular degeneration. JAMA. 2004;291(6):704-710. DOI: 10.1001/jama.292.1.43-a
19. Myakotnykh VS, Berezina DA, Borovkova TA, et al. [Comparative biochemistry of the aging process of men and women]. Advances in gerontology. 2014;27(4):612-620. Russian.